|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pang C, Guan Y, Li H, Chen W and Zhu G:
Urologic cancer in China. Jpn J Clin Oncol. 46:497–501. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer. Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carneiro BA, Meeks JJ, Kuzel TM, Scaranti
M, Abdulkadir SA and Giles FJ: Emerging therapeutic targets in
bladder cancer. Cancer Treat Rev. 41:170–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Appert-Collin A, Hubert P, Crémel G and
Bennasroune A: Role of ErbB receptor in cancer cell migration and
invasion. Front Pharmacolo. 6:2832015.
|
|
7
|
Smolensky D, Rathore K and Cekanova M:
Molecular targets in urothelialcancer: Detection, treatment, and
animal models ofbladder cancer. Drug Des Devel Ther. 10:3305–3322.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koletsas N, Koletsa T, Choidas S,
Anaqnostopoulos K, Touloupidis S, Zaramboukas T, Raptou G,
Papadopoulos N and Lambropoulou M: Immunohistochemical
investigation of HER/AKT/mTOR pathway and cellular adhesion
molecules in urothelial carcinomas. Patholog Res Int.
2017:67941502017.PubMed/NCBI
|
|
9
|
Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun
Y and Xu C: Prognostic role of HER2 expression in bladder cancer: A
systematic review and meta-analysis. Int Urol Nephrol. 47:87–94.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lo Nigro C, Ricci V, Vivenza D, Granetto
C, Fabozzi T, Miraqlio E and Merlano MC: Prognostic and predictive
biomarkers in metastatic colorectal canceranti-EGFR therapy. World
J Gastroenterol. 22:6944–6954. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hussain M, Daignault S, Agarwal N, Grivas
PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas
S, Twardowski P, et al: A randomized phase 2 trial of
gemcitabine/cisplatin with or without cetuximab in patients with
advanced urothelial carcinoma. Cancer. 120:2684–2693. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Philips GK, Halabi S, Sanford BL, Bajorin
D and Small EJ; Cancer and Leukaemia Group B, : A phase II trial of
cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced
urothelial tract carcinoma: Results of the Cancer and Leukaemia
Group B 90102. BJU Int. 101:20–25. 2008.PubMed/NCBI
|
|
14
|
Oudard S, Culine S, Vano Y, Goldwasser F,
Théodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, et
al: Multicentre randomized phase II trial of gemcitabine +
platinum, with or without trastuzumab, in advanced or metastatic
urothelial carcinoma overexpressing Her2. Eur J Cancer. 51:45–54.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Powles T, Huddart RA, Elliott T, Sarker
SJ, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J,
et al: Phase III, doubled-blind, randomized trial that compared
maintenance lapatinib versus placebo after first-line chemotherapy
in patients with human epidermal growth factor receptor
1/2-positive metastatic bladder cancer. J Clin Oncol. 35:48–55.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Y, Enting D, Rudman S and Chowdhury S:
Immunotherapy for urothelial cancer: From BCG to checkpoint
inhibitors and beyond. Expert Rev Anticancer Ther. 15:509–523.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sharma P, Callahan MK, Bono P, Kim J,
Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, et
al: Nivolumab monotherapy in recurrent metastatic urothelial
carcinoma (CheckMate 032): A multicentre, open-label, two-stage,
multi-arm, phase 1/2 trial. Lancet Oncol. 17:1590–1598. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bellmunt J, De Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced urothelial
carcioma. N Eng J Med. 376:1015–1026. 2017. View Article : Google Scholar
|
|
20
|
Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA,
Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizei A, Colaiace W,
et al: Targeted T-cell therapy in stage IV breast cancer: A phase I
clinical trial. Clin Cancer Res. 21:2305–2314. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vaishampayan U, Thakur A, Rathore R,
Kouttab N and Lum LG: Phase I study of anti-CD3 × anti-Her2
bispecific antibody in metastatic castrate resistant prostate
cancer patients. Prostate Cancer. 2015:2851932015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao M, Zhang M and Ma P: Establishment of
cisplatin-multi drug resistance cell line of human bladder cancer
T24 and its biological characteristics. Immun Clin Med. 22:338–341.
2015.(In Chinese).
|
|
23
|
Wang S, Lei T and Zhang M: The reversal
effect and its mechanisms of tetramethylpyrazine on multidrug
resistance in human bladder cancer. PLoS One. 11:e01577592016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang M, Jin S and Zhang M: The
establishment and biological characteristics evaluation of human
multidrug-resistant bladder cancer Pumc-91/ADM cell line. J Med
Res. 38:70–72. 2009.(In Chinese).
|
|
25
|
Wang S, Meng Q, Xie Qi and Zhang M: Effect
and mechanism of resveratrol on drug resistance in human bladder
cancer cells. Mol Med Rep. 15:1179–1187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiu W, Ma J, Lei T, Zhang M and Zhou S:
Immunosuppressive effect of bladder cancer on function of dendritic
cells involving of Jak2/STAT3 pathway. Oncotarget. 7:63204–63214.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma P, He Q, Li W, Li X, Han H, Jin M, Liu
C, Tao H, Ma J and Gao B: Anti-CD3 × EGFR bispecific antibody
redirects cytokine-induced killer cells to glioblastoma in vitro
and in vivo. Oncol Rep. 34:2567–2575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han H, Ma J, Zhang K, Li W, Liu C, Zhang
Y, Zhang G, Ma P, Wang L, Zhang G, et al: Bispecific anti-CD3 ×
anti-HER2 antibody mediates T cell cytolytic activity to
HER2-positive colorectal cancer in vitro and in vivo. Int J Oncol.
45:2446–2454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma J, Han H, Liu D, Li W, Feng H, Xue X,
Wu X, Niu G, Zhang G, Zhao Y, et al: HER2 as a promising target for
cytotoxicity T cells in human melanoma therapy. PLoS One.
8:e732612013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma J, Ma P, Zhao C, Xue X, Han H, Liu C,
Tao H, Xiu W, Cai J and Zhang M: B7-H3 as a promising target for
cytotoxicity T cell in human cancer therapy. Oncotarget.
7:29480–29491. 2016.PubMed/NCBI
|
|
31
|
Lum LG and Thakur A: Targeting T cells
with bispecific antibodies for cancer therapy. BioDrugs.
25:365–379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bhutani D and Lum LG: Activated T cells
armed with bispecific antibodies killtumor targets. Curr Opin
Hematol. 22:476–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Friedman M, Lindström S, Ekerljumg L,
Andersson-Svahn H, Carlsson J, Brismar H, Gedda L, Frejd FY and
Ståhl S: Engineering and characterization of a bispecific HER2 ×
EGFR-binding affibody molecule. Biotechnol Appl. Biochem.
54:121–131. 2009.
|
|
34
|
Sathaliyawala T, Kubota M, Yudanin N,
Turner D, Camp P, Thome JJ, Bickham KL, Lerner H, Goldstein M,
Sykes M, et al: Distribution and compartmentalization of human
circulating and tissue-resident memory T cell subsets. Immunity.
38:187–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
